I think it is quite possible that they could be at a similar stage within 24-36 months.
Light up the slide over the next 6-12 months and they should be able to look at a funding round of $20-30m that hopefully only represents 10-20% dilution but brings the global medical VC world to the table. There may be a couple of $2-10m upfront deals along the way or even a big partner who wants to take the iMYC program through.
Bigger thinking always brings Peptidreams comparisons to the table but for now lets stay in the valuation range of $200-400m as a target. Really good to see NEU has broken the unwritten cap of ASX $300m MCAP for biotech microcaps proving that if PYC deliver we are capable of 10-20c valuations.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)